Sellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCL

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in relapsed/refractory Diffuse Large B-Cell Lymphoma, or r/r DLBCL. The trial was an open-label single-arm multicenter Phase 2a study in China evaluating SLS009 in combination with BTK inhibitor, Brukinsa in r/r DLBCL. The results showed an overall response rate of 67%, more than double the expected overall response rate of zanubrutinib alone. Among responders, one achieved complete response while three had partial response with target lesion shrinkages of 89%, 78%, and 56%, respectively. As of the last follow-up, after the median of 4.6 months follow-up, median overall survival was not reached, and six out of 9 patients were alive.